http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014329740-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e01957626538e0c9c5ff4b6a6a33a5e3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-603 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-603 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 |
| filingDate | 2014-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6738a2cf4972bd1fef342677c2cd193c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_437434150df489ecc950d1af0c1e3c10 |
| publicationDate | 2014-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014329740-A1 |
| titleOfInvention | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| abstract | The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus , for example, Staphylococcus aureus . The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA). The invention also provides a method for preventing or treating an infectious disease caused by of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) or vancomycin-resistant Staphylococcus aureus (VRSA), comprising systemically co-administering in a synergistic combination to a subject in need thereof prophylactically or therapeutically effective amounts, individually or collectively, of a salicylic acid (SAL) or a SAL analogue and at least one additional antimicrobial agent, for example, vancomycin and/or linezolid. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016210436-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016118562-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10534895-B2 |
| priorityDate | 2008-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 373.